Fulcrum Therapeutics, Inc. Ratios

Ratios Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -802.66%-421.89%-1,732.43%-3,470.05%-12.16%
EBIT Margin -811.64%-422.97%-1,774.85%-3,945.24%-27.37%
EBITDA Margin -802.69%-423.95%-1,738.74%-3,446.49%-11.82%
Operating Margin -811.64%-422.97%-1,774.85%-3,945.24%-27.37%
Net Margin -802.66%-421.89%-1,732.43%-3,470.05%-12.16%
FCF Margin -623.34%-418.47%-1,561.23%-3,261.07%-3.12%
Efficiency
Assets Average 120.01M182.29M230.84M242.19M259.21M
Equity Average 91.17M153.36M205.24M217.07M239.11M
Invested Capital 87.15M95.18M211.54M198.94M235.19M243.03M
Asset Utilization Ratio 0.070.110.030.010.31
Leverage & Solvency
Equity Ratio 0.790.730.900.880.910.93
Valuation
Enterprise Value 291.67M264.53M681.90M343.84M181.08M12.49M
Market Capitalization 388.39M321.59M717.31M378.93M417.30M253.51M
Return Ratios
Return on Sales -8.03%-4.22%-17.32%-34.70%-0.12%
Return on Capital Employed -0.77%-0.50%-0.53%-0.48%-0.09%
Return on Assets -0.59%-0.44%-0.48%-0.40%-0.04%
Return on Equity -0.78%-0.53%-0.54%-0.45%-0.04%